Literature DB >> 7969953

Treatment of radiation-induced nervous system injury with heparin and warfarin.

M J Glantz1, P C Burger, A H Friedman, R A Radtke, E W Massey, S C Schold.   

Abstract

When radiation is used to treat nervous system cancer, exposure of adjacent normal nervous system tissue is unavoidable, and radiation-induced injury may occur. Acute injury is usually mild and transient, but late forms of radiation-induced nervous system injury are usually progressive and debilitating. Treatment with corticosteroids, surgery, and antioxidants is often ineffective. We treated 11 patients with late radiation-induced nervous system injuries (eight with cerebral radionecrosis, one with a myelopathy, and two with plexopathies, all unresponsive to dexamethasone and prednisone) with full anticoagulation. Some recovery of function occurred in five of the eight patients with cerebral radionecrosis, and all the patients with myelopathy or plexopathy. Anticoagulation was continued for 3 to 6 months. In one patient with cerebral radionecrosis, symptoms recurred after discontinuation of anticoagulation and disappeared again after reinstitution of treatment. We hypothesize that anticoagulation may arrest and reverse small-vessel endothelial injury--the fundamental lesion of radiation necrosis--and produce clinical improvement in some patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969953     DOI: 10.1212/wnl.44.11.2020

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  60 in total

Review 1.  Acute hemorrhage in late radiation necrosis of the temporal lobe: report of five cases and review of the literature.

Authors:  K M Cheng; C M Chan; Y T Fu; L C Ho; F C Cheung; C K Law
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

2.  In search of a treatment for radiation-induced optic neuropathy.

Authors:  Maanasa Indaram; Ferhina S Ali; Marc H Levin
Journal:  Curr Treat Options Neurol       Date:  2015-01       Impact factor: 3.598

Review 3.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

Review 4.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

Review 5.  Metastases to the peripheral nervous system.

Authors:  Sindhu Ramchandren; Josep Dalmau
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 6.  [HERNS. A rare, hereditary, multisystemic disease with cerebral microangiopathy].

Authors:  C Seifried; M Sitzer; J Jen; G Auburger
Journal:  Nervenarzt       Date:  2005-10       Impact factor: 1.214

Review 7.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

8.  Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Ono
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

9.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

Review 10.  Treatment of Brain Metastases.

Authors:  Xuling Lin; Lisa M DeAngelis
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.